Plasma exchange treatment for CNS inflammatory demyelinating disease

Brian G Weinshenker, B Mark Keegan, Jefrey L. Winters, Ichiro Nakashima, Kazuo Fujihara

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction Research into therapeutic applications of apheresis is limited by the rarity of many of the diseases for which plasma exchange (PLEX) is indicated and by the uncommon and often dire circumstances in which apheresis is considered for common diseases (e.g. myasthenic crisis and acute severe demyelinating disease attacks unresponsive to standard treatment). It is often difficult to perform randomized or appropriately powered studies for these reasons. As a result, case reports, case series, and underpowered trials dominate the literature with respect to clinical application of apheresis. To address this weakness, the American Society for Apheresis (ASFA) Apheresis Categories Subcommittee reviews the medical literature concerning the use of apheresis to treat disease every three years and publishes evidence-based guidelines in a special edition of the Journal of Clinical Apheresis. The guidelines include an apheresis category and a recommendation grade for each evaluated disease. The categories define the role of apheresis in disease treatment: Category I – first-line therapy, Category II – second-line therapy, Category III – role of apheresis not established so decisions should be individualized, and Category IV – apheresis is ineffective or harmful. The recommendation grade defines strength of recommendation, either strong (grade 1) or weak (grade 2), and provides an assessment of the literature quality: A – high, B – moderate, or C – low or very low quality evidence. In the recently published special edition, multiple sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and progressive multifocal leukoencephalopathy (PML) associated with natalizumab were assigned categories and recommendation grades (see Table 39.1). Strong recommendations were given for its use for acute severe attacks of central nervous system (CNS) demyelination and for NMO. Over the past decade, apheresis has been applied frequently for these indications. This chapter will review the history and current use of these techniques for CNS demyelinating diseases, as well as apheresis techniques and their complications.

Original languageEnglish (US)
Title of host publicationMultiple Sclerosis Therapeutics, Fourth Edition
PublisherCambridge University Press
Pages454-464
Number of pages11
Volume9780521766272
ISBN (Print)9781139023986, 9780521766272
DOIs
StatePublished - Dec 1 2011

Fingerprint

Blood Component Removal
Plasma Exchange
Demyelinating Diseases
Central Nervous System
Therapeutics
Neuromyelitis Optica
Acute Disseminated Encephalomyelitis
Guidelines
Therapeutic Human Experimentation
Progressive Multifocal Leukoencephalopathy
Central Nervous System Diseases
Muscle Weakness
Multiple Sclerosis
History

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Weinshenker, B. G., Keegan, B. M., Winters, J. L., Nakashima, I., & Fujihara, K. (2011). Plasma exchange treatment for CNS inflammatory demyelinating disease. In Multiple Sclerosis Therapeutics, Fourth Edition (Vol. 9780521766272, pp. 454-464). Cambridge University Press. https://doi.org/10.1017/CBO9781139023986.042

Plasma exchange treatment for CNS inflammatory demyelinating disease. / Weinshenker, Brian G; Keegan, B Mark; Winters, Jefrey L.; Nakashima, Ichiro; Fujihara, Kazuo.

Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272 Cambridge University Press, 2011. p. 454-464.

Research output: Chapter in Book/Report/Conference proceedingChapter

Weinshenker, BG, Keegan, BM, Winters, JL, Nakashima, I & Fujihara, K 2011, Plasma exchange treatment for CNS inflammatory demyelinating disease. in Multiple Sclerosis Therapeutics, Fourth Edition. vol. 9780521766272, Cambridge University Press, pp. 454-464. https://doi.org/10.1017/CBO9781139023986.042
Weinshenker BG, Keegan BM, Winters JL, Nakashima I, Fujihara K. Plasma exchange treatment for CNS inflammatory demyelinating disease. In Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272. Cambridge University Press. 2011. p. 454-464 https://doi.org/10.1017/CBO9781139023986.042
Weinshenker, Brian G ; Keegan, B Mark ; Winters, Jefrey L. ; Nakashima, Ichiro ; Fujihara, Kazuo. / Plasma exchange treatment for CNS inflammatory demyelinating disease. Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272 Cambridge University Press, 2011. pp. 454-464
@inbook{e5ac99f6396c46de8354d0c51300cbe0,
title = "Plasma exchange treatment for CNS inflammatory demyelinating disease",
abstract = "Introduction Research into therapeutic applications of apheresis is limited by the rarity of many of the diseases for which plasma exchange (PLEX) is indicated and by the uncommon and often dire circumstances in which apheresis is considered for common diseases (e.g. myasthenic crisis and acute severe demyelinating disease attacks unresponsive to standard treatment). It is often difficult to perform randomized or appropriately powered studies for these reasons. As a result, case reports, case series, and underpowered trials dominate the literature with respect to clinical application of apheresis. To address this weakness, the American Society for Apheresis (ASFA) Apheresis Categories Subcommittee reviews the medical literature concerning the use of apheresis to treat disease every three years and publishes evidence-based guidelines in a special edition of the Journal of Clinical Apheresis. The guidelines include an apheresis category and a recommendation grade for each evaluated disease. The categories define the role of apheresis in disease treatment: Category I – first-line therapy, Category II – second-line therapy, Category III – role of apheresis not established so decisions should be individualized, and Category IV – apheresis is ineffective or harmful. The recommendation grade defines strength of recommendation, either strong (grade 1) or weak (grade 2), and provides an assessment of the literature quality: A – high, B – moderate, or C – low or very low quality evidence. In the recently published special edition, multiple sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and progressive multifocal leukoencephalopathy (PML) associated with natalizumab were assigned categories and recommendation grades (see Table 39.1). Strong recommendations were given for its use for acute severe attacks of central nervous system (CNS) demyelination and for NMO. Over the past decade, apheresis has been applied frequently for these indications. This chapter will review the history and current use of these techniques for CNS demyelinating diseases, as well as apheresis techniques and their complications.",
author = "Weinshenker, {Brian G} and Keegan, {B Mark} and Winters, {Jefrey L.} and Ichiro Nakashima and Kazuo Fujihara",
year = "2011",
month = "12",
day = "1",
doi = "10.1017/CBO9781139023986.042",
language = "English (US)",
isbn = "9781139023986",
volume = "9780521766272",
pages = "454--464",
booktitle = "Multiple Sclerosis Therapeutics, Fourth Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Plasma exchange treatment for CNS inflammatory demyelinating disease

AU - Weinshenker, Brian G

AU - Keegan, B Mark

AU - Winters, Jefrey L.

AU - Nakashima, Ichiro

AU - Fujihara, Kazuo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Introduction Research into therapeutic applications of apheresis is limited by the rarity of many of the diseases for which plasma exchange (PLEX) is indicated and by the uncommon and often dire circumstances in which apheresis is considered for common diseases (e.g. myasthenic crisis and acute severe demyelinating disease attacks unresponsive to standard treatment). It is often difficult to perform randomized or appropriately powered studies for these reasons. As a result, case reports, case series, and underpowered trials dominate the literature with respect to clinical application of apheresis. To address this weakness, the American Society for Apheresis (ASFA) Apheresis Categories Subcommittee reviews the medical literature concerning the use of apheresis to treat disease every three years and publishes evidence-based guidelines in a special edition of the Journal of Clinical Apheresis. The guidelines include an apheresis category and a recommendation grade for each evaluated disease. The categories define the role of apheresis in disease treatment: Category I – first-line therapy, Category II – second-line therapy, Category III – role of apheresis not established so decisions should be individualized, and Category IV – apheresis is ineffective or harmful. The recommendation grade defines strength of recommendation, either strong (grade 1) or weak (grade 2), and provides an assessment of the literature quality: A – high, B – moderate, or C – low or very low quality evidence. In the recently published special edition, multiple sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and progressive multifocal leukoencephalopathy (PML) associated with natalizumab were assigned categories and recommendation grades (see Table 39.1). Strong recommendations were given for its use for acute severe attacks of central nervous system (CNS) demyelination and for NMO. Over the past decade, apheresis has been applied frequently for these indications. This chapter will review the history and current use of these techniques for CNS demyelinating diseases, as well as apheresis techniques and their complications.

AB - Introduction Research into therapeutic applications of apheresis is limited by the rarity of many of the diseases for which plasma exchange (PLEX) is indicated and by the uncommon and often dire circumstances in which apheresis is considered for common diseases (e.g. myasthenic crisis and acute severe demyelinating disease attacks unresponsive to standard treatment). It is often difficult to perform randomized or appropriately powered studies for these reasons. As a result, case reports, case series, and underpowered trials dominate the literature with respect to clinical application of apheresis. To address this weakness, the American Society for Apheresis (ASFA) Apheresis Categories Subcommittee reviews the medical literature concerning the use of apheresis to treat disease every three years and publishes evidence-based guidelines in a special edition of the Journal of Clinical Apheresis. The guidelines include an apheresis category and a recommendation grade for each evaluated disease. The categories define the role of apheresis in disease treatment: Category I – first-line therapy, Category II – second-line therapy, Category III – role of apheresis not established so decisions should be individualized, and Category IV – apheresis is ineffective or harmful. The recommendation grade defines strength of recommendation, either strong (grade 1) or weak (grade 2), and provides an assessment of the literature quality: A – high, B – moderate, or C – low or very low quality evidence. In the recently published special edition, multiple sclerosis (MS), neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and progressive multifocal leukoencephalopathy (PML) associated with natalizumab were assigned categories and recommendation grades (see Table 39.1). Strong recommendations were given for its use for acute severe attacks of central nervous system (CNS) demyelination and for NMO. Over the past decade, apheresis has been applied frequently for these indications. This chapter will review the history and current use of these techniques for CNS demyelinating diseases, as well as apheresis techniques and their complications.

UR - http://www.scopus.com/inward/record.url?scp=84927072589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927072589&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139023986.042

DO - 10.1017/CBO9781139023986.042

M3 - Chapter

SN - 9781139023986

SN - 9780521766272

VL - 9780521766272

SP - 454

EP - 464

BT - Multiple Sclerosis Therapeutics, Fourth Edition

PB - Cambridge University Press

ER -